Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fragile X Syndrome | 111 | 2021 | 169 | 26.860 |
Why?
|
Fragile X Mental Retardation Protein | 56 | 2021 | 101 | 6.930 |
Why?
|
Tremor | 26 | 2021 | 124 | 4.470 |
Why?
|
Ataxia | 24 | 2021 | 76 | 4.420 |
Why?
|
Niemann-Pick Disease, Type C | 11 | 2021 | 15 | 4.400 |
Why?
|
Mutation | 49 | 2021 | 457 | 3.460 |
Why?
|
Child | 66 | 2021 | 1547 | 3.080 |
Why?
|
Sleep Apnea, Central | 19 | 2021 | 25 | 3.030 |
Why?
|
Humans | 218 | 2022 | 30741 | 2.730 |
Why?
|
Homeodomain Proteins | 28 | 2021 | 57 | 2.670 |
Why?
|
Adolescent | 60 | 2021 | 2627 | 2.630 |
Why?
|
Heterozygote | 23 | 2021 | 106 | 2.570 |
Why?
|
Transcription Factors | 29 | 2019 | 179 | 2.540 |
Why?
|
Child, Preschool | 51 | 2021 | 803 | 2.470 |
Why?
|
Female | 146 | 2021 | 18107 | 2.320 |
Why?
|
Male | 148 | 2021 | 17552 | 2.310 |
Why?
|
Hypoventilation | 20 | 2021 | 37 | 2.140 |
Why?
|
Trinucleotide Repeat Expansion | 17 | 2021 | 40 | 2.110 |
Why?
|
Phenotype | 33 | 2021 | 368 | 2.070 |
Why?
|
Adult | 81 | 2021 | 9760 | 1.890 |
Why?
|
Autistic Disorder | 9 | 2020 | 45 | 1.880 |
Why?
|
Sudden Infant Death | 13 | 2013 | 34 | 1.850 |
Why?
|
Indoles | 4 | 2019 | 68 | 1.680 |
Why?
|
Young Adult | 40 | 2021 | 2249 | 1.660 |
Why?
|
Language | 5 | 2021 | 78 | 1.650 |
Why?
|
Nerve Tissue Proteins | 21 | 2020 | 172 | 1.640 |
Why?
|
Cognition Disorders | 15 | 2018 | 1064 | 1.610 |
Why?
|
Cyclodextrins | 2 | 2020 | 7 | 1.570 |
Why?
|
Language Tests | 6 | 2021 | 37 | 1.530 |
Why?
|
Epilepsy | 9 | 2017 | 108 | 1.490 |
Why?
|
Infant | 37 | 2021 | 660 | 1.460 |
Why?
|
Receptor, Metabotropic Glutamate 5 | 7 | 2019 | 15 | 1.380 |
Why?
|
Chromosome Disorders | 7 | 2022 | 17 | 1.310 |
Why?
|
Seizures | 7 | 2020 | 86 | 1.310 |
Why?
|
Genetic Predisposition to Disease | 20 | 2021 | 473 | 1.290 |
Why?
|
Genetic Testing | 10 | 2016 | 76 | 1.280 |
Why?
|
Registries | 5 | 2020 | 203 | 1.280 |
Why?
|
Attention | 4 | 2020 | 163 | 1.250 |
Why?
|
Trinucleotide Repeats | 8 | 2021 | 12 | 1.210 |
Why?
|
Alleles | 22 | 2021 | 230 | 1.200 |
Why?
|
Clinical Trials as Topic | 7 | 2021 | 386 | 1.170 |
Why?
|
Neuropsychological Tests | 21 | 2021 | 1278 | 1.150 |
Why?
|
Autonomic Nervous System Diseases | 11 | 2016 | 30 | 1.110 |
Why?
|
Glutamates | 2 | 2020 | 18 | 1.050 |
Why?
|
Receptors, Metabotropic Glutamate | 7 | 2019 | 18 | 1.040 |
Why?
|
Carrier Proteins | 4 | 2020 | 130 | 1.030 |
Why?
|
Cognition | 11 | 2021 | 1141 | 1.010 |
Why?
|
Executive Function | 6 | 2019 | 104 | 1.010 |
Why?
|
Gastrointestinal Diseases | 2 | 2020 | 46 | 0.980 |
Why?
|
Case-Control Studies | 25 | 2021 | 694 | 0.940 |
Why?
|
Developmental Disabilities | 7 | 2021 | 26 | 0.920 |
Why?
|
Phosphodiesterase 4 Inhibitors | 1 | 2021 | 1 | 0.920 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2021 | 5 | 0.920 |
Why?
|
Parkinsonian Disorders | 4 | 2020 | 186 | 0.900 |
Why?
|
Pupil | 2 | 2019 | 5 | 0.900 |
Why?
|
Animals | 39 | 2021 | 5221 | 0.890 |
Why?
|
Evoked Potentials, Auditory | 1 | 2020 | 4 | 0.890 |
Why?
|
Neonatal Screening | 4 | 2018 | 6 | 0.880 |
Why?
|
Soybeans | 1 | 2020 | 2 | 0.880 |
Why?
|
Neurotransmitter Agents | 3 | 2017 | 23 | 0.880 |
Why?
|
Food, Formulated | 1 | 2020 | 9 | 0.880 |
Why?
|
Brain Waves | 1 | 2020 | 9 | 0.870 |
Why?
|
Hypersensitivity | 2 | 2020 | 54 | 0.870 |
Why?
|
Infant Formula | 1 | 2020 | 24 | 0.860 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 2020 | 71 | 0.850 |
Why?
|
Anesthetics | 1 | 2020 | 23 | 0.840 |
Why?
|
Intellectual Disability | 9 | 2020 | 43 | 0.830 |
Why?
|
Toilet Training | 1 | 2019 | 1 | 0.830 |
Why?
|
Fixation, Ocular | 2 | 2019 | 8 | 0.830 |
Why?
|
Auditory Perception | 1 | 2020 | 50 | 0.830 |
Why?
|
Genetic Association Studies | 6 | 2022 | 90 | 0.830 |
Why?
|
Behavioral Symptoms | 1 | 2019 | 17 | 0.820 |
Why?
|
Middle Aged | 47 | 2021 | 11256 | 0.820 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 41 | 0.820 |
Why?
|
Vocabulary | 1 | 2019 | 12 | 0.810 |
Why?
|
Treatment Outcome | 18 | 2021 | 3850 | 0.810 |
Why?
|
Comprehension | 1 | 2019 | 31 | 0.800 |
Why?
|
Language Development Disorders | 1 | 2019 | 17 | 0.800 |
Why?
|
Behavior | 3 | 2016 | 33 | 0.790 |
Why?
|
RNA-Binding Proteins | 8 | 2005 | 26 | 0.790 |
Why?
|
Genetic Counseling | 4 | 2016 | 12 | 0.790 |
Why?
|
Genetic Therapy | 5 | 2016 | 92 | 0.760 |
Why?
|
Cyclic AMP | 10 | 1998 | 33 | 0.750 |
Why?
|
Brain | 23 | 2015 | 1574 | 0.720 |
Why?
|
RNA, Messenger | 12 | 2021 | 361 | 0.710 |
Why?
|
Gait | 4 | 2020 | 388 | 0.700 |
Why?
|
Mice | 25 | 2019 | 1843 | 0.690 |
Why?
|
Mental Disorders | 4 | 2018 | 202 | 0.680 |
Why?
|
Intelligence | 3 | 2016 | 28 | 0.670 |
Why?
|
Comorbidity | 6 | 2020 | 562 | 0.660 |
Why?
|
Enzyme Replacement Therapy | 1 | 2016 | 1 | 0.660 |
Why?
|
Polymorphism, Genetic | 11 | 2010 | 96 | 0.650 |
Why?
|
Hypothalamic Diseases | 5 | 2015 | 6 | 0.630 |
Why?
|
Psychometrics | 8 | 2021 | 286 | 0.630 |
Why?
|
Child Behavior Disorders | 3 | 2017 | 24 | 0.620 |
Why?
|
Reproducibility of Results | 10 | 2021 | 875 | 0.620 |
Why?
|
Baclofen | 2 | 2012 | 15 | 0.620 |
Why?
|
Severity of Illness Index | 8 | 2020 | 1233 | 0.610 |
Why?
|
Down Syndrome | 4 | 2021 | 11 | 0.610 |
Why?
|
Infant, Newborn | 18 | 2020 | 751 | 0.610 |
Why?
|
Sex Factors | 7 | 2020 | 535 | 0.610 |
Why?
|
Adaptation, Psychological | 2 | 2017 | 178 | 0.610 |
Why?
|
Ketosis | 3 | 2005 | 5 | 0.600 |
Why?
|
Psychiatric Status Rating Scales | 3 | 2014 | 386 | 0.590 |
Why?
|
Disease Management | 1 | 2016 | 149 | 0.580 |
Why?
|
Imidazoles | 3 | 2021 | 74 | 0.580 |
Why?
|
Neurons | 11 | 2015 | 397 | 0.580 |
Why?
|
Aged | 39 | 2020 | 10156 | 0.570 |
Why?
|
Mice, Knockout | 10 | 2019 | 384 | 0.570 |
Why?
|
Cholesterol | 1 | 2014 | 65 | 0.560 |
Why?
|
Pilot Projects | 8 | 2021 | 440 | 0.560 |
Why?
|
Health Surveys | 3 | 2012 | 101 | 0.560 |
Why?
|
Polymerase Chain Reaction | 5 | 2021 | 209 | 0.550 |
Why?
|
Double-Blind Method | 6 | 2020 | 550 | 0.530 |
Why?
|
Anxiety Disorders | 3 | 2014 | 175 | 0.530 |
Why?
|
Point Mutation | 5 | 2007 | 38 | 0.520 |
Why?
|
Nervous System | 1 | 2012 | 13 | 0.500 |
Why?
|
Chromosome Deletion | 6 | 2022 | 25 | 0.490 |
Why?
|
DNA Mutational Analysis | 14 | 2017 | 76 | 0.490 |
Why?
|
Psychotropic Drugs | 4 | 2017 | 29 | 0.480 |
Why?
|
Apolipoproteins E | 8 | 2005 | 202 | 0.480 |
Why?
|
Piperidines | 2 | 2012 | 36 | 0.450 |
Why?
|
Alzheimer Disease | 8 | 2014 | 1751 | 0.450 |
Why?
|
DNA Methylation | 6 | 2017 | 165 | 0.440 |
Why?
|
Neuroblastoma | 9 | 2006 | 24 | 0.440 |
Why?
|
Gene Deletion | 5 | 2013 | 57 | 0.430 |
Why?
|
Genotype | 18 | 2019 | 447 | 0.430 |
Why?
|
DNA | 11 | 2013 | 140 | 0.420 |
Why?
|
Antipsychotic Agents | 3 | 2019 | 90 | 0.420 |
Why?
|
Placebos | 3 | 2021 | 90 | 0.420 |
Why?
|
Neuronal Ceroid-Lipofuscinoses | 2 | 2020 | 7 | 0.420 |
Why?
|
Aged, 80 and over | 20 | 2020 | 5172 | 0.420 |
Why?
|
Phosphorylcholine | 2 | 2020 | 5 | 0.410 |
Why?
|
Bile Acids and Salts | 3 | 2020 | 14 | 0.410 |
Why?
|
Disease Progression | 8 | 2021 | 851 | 0.410 |
Why?
|
Blood Platelets | 4 | 2001 | 53 | 0.400 |
Why?
|
Excitatory Amino Acid Antagonists | 3 | 2018 | 22 | 0.390 |
Why?
|
Primary Ovarian Insufficiency | 3 | 2021 | 7 | 0.380 |
Why?
|
Lithium Carbonate | 1 | 2008 | 4 | 0.380 |
Why?
|
Peptides | 4 | 2016 | 113 | 0.380 |
Why?
|
Genetic Variation | 5 | 2019 | 117 | 0.380 |
Why?
|
Hirschsprung Disease | 5 | 2012 | 11 | 0.370 |
Why?
|
Retrospective Studies | 9 | 2020 | 3456 | 0.370 |
Why?
|
Autonomic Nervous System | 5 | 2011 | 26 | 0.370 |
Why?
|
Rett Syndrome | 2 | 2019 | 4 | 0.360 |
Why?
|
Obesity | 4 | 2015 | 322 | 0.360 |
Why?
|
Abnormalities, Multiple | 4 | 2010 | 19 | 0.360 |
Why?
|
Cerebellum | 5 | 2018 | 58 | 0.350 |
Why?
|
Disease Models, Animal | 7 | 2019 | 831 | 0.350 |
Why?
|
Guidelines as Topic | 1 | 2007 | 78 | 0.340 |
Why?
|
Siblings | 2 | 2016 | 19 | 0.340 |
Why?
|
Chromosomes, Human, X | 3 | 2007 | 9 | 0.330 |
Why?
|
Dioxoles | 1 | 2006 | 10 | 0.330 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2007 | 38 | 0.330 |
Why?
|
Receptors, AMPA | 1 | 2006 | 13 | 0.330 |
Why?
|
Age of Onset | 9 | 2019 | 115 | 0.330 |
Why?
|
Cohort Studies | 8 | 2016 | 1959 | 0.330 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 361 | 0.330 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2006 | 2 | 0.330 |
Why?
|
Glutathione Transferase | 1 | 2006 | 8 | 0.330 |
Why?
|
Nicotine | 1 | 2006 | 8 | 0.330 |
Why?
|
Pedigree | 7 | 2019 | 86 | 0.330 |
Why?
|
Nootropic Agents | 2 | 2020 | 14 | 0.330 |
Why?
|
Chromosomes, Human, Pair 22 | 6 | 2022 | 14 | 0.320 |
Why?
|
Family Health | 5 | 2010 | 41 | 0.320 |
Why?
|
DNA Repeat Expansion | 4 | 2016 | 6 | 0.320 |
Why?
|
Receptors, Serotonin | 8 | 1993 | 21 | 0.310 |
Why?
|
Hybrid Cells | 8 | 1988 | 11 | 0.310 |
Why?
|
Magnetic Resonance Imaging | 12 | 2018 | 1244 | 0.310 |
Why?
|
Prevalence | 3 | 2020 | 546 | 0.300 |
Why?
|
Growth | 1 | 2005 | 6 | 0.300 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2005 | 6 | 0.300 |
Why?
|
Ketone Bodies | 1 | 2005 | 5 | 0.300 |
Why?
|
Intracellular Signaling Peptides and Proteins | 3 | 2020 | 65 | 0.300 |
Why?
|
Risk Factors | 11 | 2021 | 2611 | 0.300 |
Why?
|
Feasibility Studies | 5 | 2021 | 283 | 0.300 |
Why?
|
Child Development | 2 | 2010 | 80 | 0.300 |
Why?
|
Administration, Oral | 3 | 2012 | 165 | 0.300 |
Why?
|
Serotonin | 8 | 2008 | 42 | 0.300 |
Why?
|
Dosage Compensation, Genetic | 1 | 2005 | 2 | 0.300 |
Why?
|
Patient Care Team | 2 | 2020 | 143 | 0.300 |
Why?
|
Membrane Glycoproteins | 3 | 2017 | 107 | 0.290 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2019 | 331 | 0.290 |
Why?
|
Dendritic Spines | 3 | 2013 | 12 | 0.290 |
Why?
|
Longitudinal Studies | 8 | 2020 | 1432 | 0.280 |
Why?
|
Atrophy | 4 | 2017 | 107 | 0.280 |
Why?
|
Rare Diseases | 2 | 2021 | 15 | 0.280 |
Why?
|
Mitochondrial Proteins | 3 | 2013 | 40 | 0.270 |
Why?
|
Twins, Monozygotic | 2 | 2015 | 7 | 0.270 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 2 | 2020 | 6 | 0.270 |
Why?
|
Aminopeptidases | 2 | 2020 | 7 | 0.270 |
Why?
|
Serine Proteases | 2 | 2020 | 7 | 0.270 |
Why?
|
United States | 10 | 2020 | 2467 | 0.270 |
Why?
|
Quality of Life | 4 | 2016 | 636 | 0.260 |
Why?
|
Computers | 2 | 2021 | 26 | 0.260 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 3 | 2012 | 36 | 0.260 |
Why?
|
Hyperkinesis | 2 | 2013 | 12 | 0.260 |
Why?
|
Learning | 4 | 2013 | 89 | 0.260 |
Why?
|
Forecasting | 3 | 2017 | 130 | 0.260 |
Why?
|
Signal Transduction | 5 | 2021 | 582 | 0.260 |
Why?
|
Adrenergic alpha-Agonists | 3 | 2017 | 18 | 0.260 |
Why?
|
Age Factors | 6 | 2021 | 941 | 0.260 |
Why?
|
Checklist | 2 | 2014 | 41 | 0.260 |
Why?
|
Epilepsy, Generalized | 1 | 2002 | 8 | 0.250 |
Why?
|
Huntington Disease | 3 | 2008 | 60 | 0.250 |
Why?
|
Epilepsies, Partial | 1 | 2002 | 23 | 0.250 |
Why?
|
Mosaicism | 5 | 2016 | 8 | 0.250 |
Why?
|
Psychomotor Performance | 3 | 2020 | 245 | 0.250 |
Why?
|
Autophagy | 2 | 2020 | 31 | 0.240 |
Why?
|
Syndrome | 11 | 2011 | 108 | 0.240 |
Why?
|
Carnitine | 1 | 2001 | 8 | 0.240 |
Why?
|
Stress, Psychological | 3 | 2021 | 278 | 0.240 |
Why?
|
Diffusion Tensor Imaging | 2 | 2020 | 77 | 0.230 |
Why?
|
Dried Blood Spot Testing | 2 | 2018 | 4 | 0.230 |
Why?
|
Repetitive Sequences, Nucleic Acid | 2 | 2019 | 8 | 0.230 |
Why?
|
Minocycline | 2 | 2012 | 8 | 0.230 |
Why?
|
Genes, Homeobox | 1 | 2021 | 5 | 0.230 |
Why?
|
Hair | 1 | 2021 | 4 | 0.230 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2021 | 10 | 0.230 |
Why?
|
Gene-Environment Interaction | 1 | 2021 | 19 | 0.230 |
Why?
|
Neural Stem Cells | 1 | 2021 | 17 | 0.230 |
Why?
|
Movement Disorders | 2 | 2016 | 140 | 0.230 |
Why?
|
Anticonvulsants | 3 | 2010 | 107 | 0.220 |
Why?
|
Contusions | 1 | 2001 | 2 | 0.220 |
Why?
|
Brain Chemistry | 5 | 2013 | 51 | 0.220 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2021 | 12 | 0.220 |
Why?
|
Cross-Over Studies | 1 | 2021 | 81 | 0.220 |
Why?
|
Hallucinations | 3 | 2011 | 94 | 0.220 |
Why?
|
Ovary | 1 | 2021 | 35 | 0.220 |
Why?
|
Glycine | 1 | 2020 | 10 | 0.220 |
Why?
|
Hydrocortisone | 1 | 2021 | 57 | 0.220 |
Why?
|
Interdisciplinary Communication | 3 | 2020 | 32 | 0.220 |
Why?
|
Alkynes | 1 | 2020 | 12 | 0.220 |
Why?
|
Azides | 1 | 2020 | 5 | 0.220 |
Why?
|
Mothers | 3 | 2021 | 178 | 0.220 |
Why?
|
Accidental Falls | 2 | 2020 | 112 | 0.220 |
Why?
|
Enzyme Inhibitors | 2 | 2012 | 160 | 0.220 |
Why?
|
Infusions, Intraventricular | 1 | 2020 | 1 | 0.210 |
Why?
|
Infusion Pumps | 1 | 2020 | 16 | 0.210 |
Why?
|
Databases, Factual | 2 | 2020 | 372 | 0.210 |
Why?
|
Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.210 |
Why?
|
Reflex, Pupillary | 1 | 2019 | 2 | 0.210 |
Why?
|
Menopause | 1 | 2021 | 118 | 0.210 |
Why?
|
Irritable Mood | 1 | 2019 | 6 | 0.210 |
Why?
|
Self-Injurious Behavior | 1 | 2019 | 4 | 0.210 |
Why?
|
Psychomotor Agitation | 1 | 2019 | 16 | 0.210 |
Why?
|
Facial Expression | 1 | 2019 | 16 | 0.210 |
Why?
|
Prenatal Diagnosis | 1 | 2000 | 23 | 0.200 |
Why?
|
Child Development Disorders, Pervasive | 3 | 2014 | 30 | 0.200 |
Why?
|
Personality Assessment | 2 | 2012 | 41 | 0.200 |
Why?
|
Early Diagnosis | 3 | 2017 | 76 | 0.200 |
Why?
|
Social Behavior | 2 | 2019 | 109 | 0.200 |
Why?
|
Matrix Attachment Region Binding Proteins | 1 | 2019 | 1 | 0.200 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 4 | 2007 | 13 | 0.200 |
Why?
|
Interpersonal Relations | 1 | 2020 | 117 | 0.200 |
Why?
|
Speech | 1 | 2019 | 26 | 0.200 |
Why?
|
Exome | 2 | 2017 | 9 | 0.200 |
Why?
|
Aggression | 1 | 2019 | 35 | 0.200 |
Why?
|
Recombinant Proteins | 1 | 2020 | 308 | 0.200 |
Why?
|
Preventive Health Services | 1 | 2019 | 15 | 0.200 |
Why?
|
Chromatography, Liquid | 3 | 2020 | 19 | 0.200 |
Why?
|
Agenesis of Corpus Callosum | 2 | 1999 | 4 | 0.200 |
Why?
|
X Chromosome | 2 | 1999 | 11 | 0.200 |
Why?
|
Glutamic Acid | 1 | 2019 | 35 | 0.190 |
Why?
|
Biomechanical Phenomena | 3 | 2016 | 712 | 0.190 |
Why?
|
Communication | 1 | 2020 | 119 | 0.190 |
Why?
|
Asymptomatic Diseases | 1 | 2019 | 21 | 0.190 |
Why?
|
Parkinson Disease | 5 | 2011 | 1136 | 0.190 |
Why?
|
Emotions | 1 | 2019 | 96 | 0.190 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2018 | 527 | 0.190 |
Why?
|
DNA-Binding Proteins | 3 | 2011 | 258 | 0.190 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 389 | 0.190 |
Why?
|
Basal Ganglia | 1 | 2018 | 31 | 0.190 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 33 | 0.190 |
Why?
|
Postural Balance | 2 | 2020 | 121 | 0.190 |
Why?
|
Gait Disorders, Neurologic | 2 | 2018 | 150 | 0.190 |
Why?
|
Cholecystokinin | 2 | 2011 | 9 | 0.190 |
Why?
|
White Matter | 1 | 2020 | 124 | 0.180 |
Why?
|
Infusions, Spinal | 1 | 2018 | 4 | 0.180 |
Why?
|
Follow-Up Studies | 6 | 2017 | 2046 | 0.180 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 109 | 0.180 |
Why?
|
Gene Expression Regulation | 2 | 2015 | 348 | 0.180 |
Why?
|
Acyltransferases | 1 | 2017 | 3 | 0.180 |
Why?
|
Spinal Puncture | 1 | 2018 | 23 | 0.180 |
Why?
|
Walking | 1 | 2020 | 241 | 0.180 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2017 | 39 | 0.180 |
Why?
|
Central Nervous System Stimulants | 2 | 2012 | 56 | 0.180 |
Why?
|
Bone Diseases, Metabolic | 1 | 2017 | 15 | 0.180 |
Why?
|
Neurosurgical Procedures | 1 | 2020 | 163 | 0.180 |
Why?
|
Memory Disorders | 3 | 2016 | 180 | 0.180 |
Why?
|
Mutation, Missense | 4 | 2019 | 29 | 0.180 |
Why?
|
Disabled Persons | 1 | 2019 | 110 | 0.180 |
Why?
|
DNA, Mitochondrial | 2 | 2011 | 7 | 0.170 |
Why?
|
Cell Line | 11 | 2013 | 354 | 0.170 |
Why?
|
Dopamine | 2 | 2012 | 162 | 0.170 |
Why?
|
Electroencephalography | 4 | 2021 | 144 | 0.170 |
Why?
|
Health Behavior | 1 | 2019 | 175 | 0.170 |
Why?
|
Databases as Topic | 1 | 2017 | 22 | 0.170 |
Why?
|
Pyridines | 1 | 2017 | 48 | 0.170 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2017 | 48 | 0.170 |
Why?
|
Fibroblasts | 3 | 2017 | 98 | 0.170 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 69 | 0.170 |
Why?
|
Eye Movements | 2 | 2019 | 25 | 0.170 |
Why?
|
Tuberous Sclerosis | 1 | 2016 | 14 | 0.160 |
Why?
|
Memory | 2 | 2013 | 333 | 0.160 |
Why?
|
Sleep | 1 | 2020 | 340 | 0.160 |
Why?
|
Exons | 5 | 2011 | 46 | 0.160 |
Why?
|
Sinus Arrest, Cardiac | 1 | 2016 | 2 | 0.160 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 9 | 0.160 |
Why?
|
Posture | 1 | 2016 | 88 | 0.160 |
Why?
|
Obesity Hypoventilation Syndrome | 1 | 2015 | 1 | 0.160 |
Why?
|
Orexin Receptors | 1 | 2015 | 1 | 0.160 |
Why?
|
Ganglioneuroblastoma | 1 | 2015 | 1 | 0.160 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 473 | 0.150 |
Why?
|
Ganglioneuroma | 1 | 2015 | 6 | 0.150 |
Why?
|
Diseases in Twins | 2 | 2015 | 9 | 0.150 |
Why?
|
Tandem Mass Spectrometry | 3 | 2020 | 23 | 0.150 |
Why?
|
Demography | 1 | 2016 | 82 | 0.150 |
Why?
|
Cricetinae | 10 | 1996 | 50 | 0.150 |
Why?
|
Leukoencephalopathies | 1 | 2015 | 9 | 0.150 |
Why?
|
Lithium Compounds | 2 | 2012 | 3 | 0.150 |
Why?
|
Gangliosides | 2 | 1985 | 8 | 0.150 |
Why?
|
Educational Status | 3 | 2013 | 285 | 0.150 |
Why?
|
Mitochondrial Myopathies | 1 | 1994 | 1 | 0.150 |
Why?
|
Haplotypes | 2 | 2006 | 68 | 0.150 |
Why?
|
Nervous System Malformations | 1 | 2014 | 3 | 0.150 |
Why?
|
Gemfibrozil | 1 | 2015 | 23 | 0.140 |
Why?
|
Nuclear Proteins | 4 | 2008 | 96 | 0.140 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 957 | 0.140 |
Why?
|
Epigenesis, Genetic | 2 | 2016 | 91 | 0.140 |
Why?
|
Promoter Regions, Genetic | 4 | 2015 | 106 | 0.140 |
Why?
|
Cells, Cultured | 5 | 2012 | 791 | 0.140 |
Why?
|
African Americans | 4 | 2013 | 780 | 0.140 |
Why?
|
Attitude to Health | 1 | 2015 | 116 | 0.140 |
Why?
|
Anxiety | 2 | 2015 | 159 | 0.140 |
Why?
|
DiGeorge Syndrome | 1 | 1994 | 1 | 0.140 |
Why?
|
Gene Frequency | 7 | 2011 | 86 | 0.140 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1994 | 6 | 0.140 |
Why?
|
Protein Biosynthesis | 3 | 2021 | 27 | 0.140 |
Why?
|
Multigene Family | 1 | 1994 | 13 | 0.140 |
Why?
|
Antidepressive Agents | 2 | 2019 | 107 | 0.140 |
Why?
|
PPAR alpha | 1 | 2015 | 37 | 0.140 |
Why?
|
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I | 1 | 2013 | 1 | 0.140 |
Why?
|
Chromosome Aberrations | 1 | 1994 | 17 | 0.140 |
Why?
|
Disability Evaluation | 1 | 2016 | 330 | 0.140 |
Why?
|
Brain-Derived Neurotrophic Factor | 2 | 2012 | 43 | 0.140 |
Why?
|
Space Perception | 3 | 2009 | 45 | 0.140 |
Why?
|
Parents | 2 | 2017 | 102 | 0.140 |
Why?
|
Motor Activity | 3 | 2020 | 395 | 0.140 |
Why?
|
Face | 1 | 1994 | 17 | 0.130 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 228 | 0.130 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2013 | 20 | 0.130 |
Why?
|
Receptors, Dopamine | 3 | 2001 | 30 | 0.130 |
Why?
|
Myotonic Dystrophy | 1 | 2013 | 1 | 0.130 |
Why?
|
Physicians | 2 | 2016 | 112 | 0.130 |
Why?
|
Education | 1 | 2013 | 42 | 0.130 |
Why?
|
Astrocytes | 1 | 2015 | 133 | 0.130 |
Why?
|
Language Disorders | 1 | 2013 | 12 | 0.130 |
Why?
|
Pantothenate Kinase-Associated Neurodegeneration | 1 | 2013 | 4 | 0.130 |
Why?
|
Haploinsufficiency | 1 | 2013 | 2 | 0.130 |
Why?
|
Interneurons | 1 | 2013 | 5 | 0.130 |
Why?
|
Iron | 1 | 2013 | 19 | 0.130 |
Why?
|
Iron Overload | 1 | 2012 | 5 | 0.130 |
Why?
|
Heart Diseases | 1 | 2014 | 102 | 0.130 |
Why?
|
Pituitary Adenylate Cyclase-Activating Polypeptide | 2 | 2011 | 3 | 0.130 |
Why?
|
Membrane Transport Proteins | 2 | 2003 | 52 | 0.130 |
Why?
|
Cerebral Cortex | 2 | 2008 | 203 | 0.130 |
Why?
|
Models, Genetic | 1 | 2012 | 44 | 0.130 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2012 | 4 | 0.130 |
Why?
|
Germ Cells | 1 | 2012 | 1 | 0.130 |
Why?
|
Cutis Laxa | 1 | 2012 | 1 | 0.120 |
Why?
|
Proton-Translocating ATPases | 1 | 2012 | 5 | 0.120 |
Why?
|
Logistic Models | 3 | 2019 | 479 | 0.120 |
Why?
|
Nerve Net | 1 | 2013 | 54 | 0.120 |
Why?
|
Heart Defects, Congenital | 1 | 1994 | 66 | 0.120 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2012 | 42 | 0.120 |
Why?
|
Receptor, Serotonin, 5-HT1A | 2 | 2011 | 3 | 0.120 |
Why?
|
Receptors, GABA | 1 | 2012 | 5 | 0.120 |
Why?
|
Deglutition | 1 | 2012 | 10 | 0.120 |
Why?
|
Enkephalin, Leucine | 3 | 1988 | 6 | 0.120 |
Why?
|
Indans | 1 | 2012 | 12 | 0.120 |
Why?
|
Vitamin E | 1 | 2012 | 43 | 0.120 |
Why?
|
Cooperative Behavior | 1 | 2012 | 88 | 0.120 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2011 | 18 | 0.120 |
Why?
|
Referral and Consultation | 1 | 2012 | 93 | 0.120 |
Why?
|
Ion Transport | 1 | 2011 | 36 | 0.110 |
Why?
|
Asian Continental Ancestry Group | 1 | 2011 | 13 | 0.110 |
Why?
|
Peptide Fragments | 1 | 2011 | 121 | 0.110 |
Why?
|
Antioxidants | 1 | 2012 | 70 | 0.110 |
Why?
|
Neurodegenerative Diseases | 1 | 2012 | 112 | 0.110 |
Why?
|
Zebrafish Proteins | 1 | 2011 | 10 | 0.110 |
Why?
|
Zinc | 1 | 2011 | 39 | 0.110 |
Why?
|
Cricetulus | 7 | 1986 | 19 | 0.110 |
Why?
|
Drosophila Proteins | 1 | 2011 | 13 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2010 | 15 | 0.110 |
Why?
|
Embryo, Mammalian | 3 | 2004 | 37 | 0.110 |
Why?
|
Corpus Striatum | 2 | 2008 | 116 | 0.110 |
Why?
|
Melatonin | 1 | 2012 | 91 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 41 | 0.110 |
Why?
|
Sympathetic Nervous System | 2 | 2007 | 14 | 0.110 |
Why?
|
Carrier State | 1 | 2010 | 52 | 0.110 |
Why?
|
Heart Rate | 2 | 2011 | 165 | 0.110 |
Why?
|
Introns | 2 | 2007 | 18 | 0.100 |
Why?
|
Gene Transfer Techniques | 2 | 2008 | 37 | 0.100 |
Why?
|
Mitochondria | 1 | 2010 | 87 | 0.100 |
Why?
|
Amyloid beta-Peptides | 1 | 2011 | 229 | 0.100 |
Why?
|
Genetic Markers | 3 | 2005 | 65 | 0.100 |
Why?
|
Maze Learning | 1 | 2009 | 22 | 0.100 |
Why?
|
Sensory Gating | 1 | 2009 | 3 | 0.100 |
Why?
|
Time Factors | 5 | 2020 | 1911 | 0.100 |
Why?
|
Reflex, Startle | 1 | 2009 | 4 | 0.100 |
Why?
|
Reaction Time | 4 | 2015 | 120 | 0.100 |
Why?
|
Alprostadil | 5 | 1993 | 11 | 0.100 |
Why?
|
Base Sequence | 4 | 2012 | 162 | 0.100 |
Why?
|
Neural Inhibition | 1 | 2009 | 9 | 0.100 |
Why?
|
Mass Spectrometry | 1 | 2009 | 36 | 0.100 |
Why?
|
Early Medical Intervention | 2 | 2020 | 16 | 0.100 |
Why?
|
Receptor, Serotonin, 5-HT2A | 1 | 2008 | 2 | 0.100 |
Why?
|
Blood Cell Count | 1 | 2008 | 19 | 0.090 |
Why?
|
Neurturin | 1 | 2008 | 22 | 0.090 |
Why?
|
Primary Cell Culture | 2 | 2021 | 24 | 0.090 |
Why?
|
Psychological Tests | 1 | 2008 | 64 | 0.090 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 403 | 0.090 |
Why?
|
Thyrotropin | 1 | 2008 | 43 | 0.090 |
Why?
|
Phosphoproteins | 1 | 1988 | 36 | 0.090 |
Why?
|
Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.090 |
Why?
|
Apolipoprotein E4 | 6 | 2005 | 208 | 0.090 |
Why?
|
Respiration, Artificial | 3 | 2016 | 111 | 0.090 |
Why?
|
Death, Sudden | 1 | 2008 | 14 | 0.090 |
Why?
|
Sequence Analysis, DNA | 3 | 2015 | 97 | 0.090 |
Why?
|
Synapses | 1 | 2008 | 47 | 0.090 |
Why?
|
Health Status | 3 | 2019 | 252 | 0.090 |
Why?
|
Vagus Nerve | 1 | 2007 | 14 | 0.090 |
Why?
|
Regression Analysis | 3 | 2015 | 323 | 0.090 |
Why?
|
Genetic Linkage | 2 | 1999 | 68 | 0.090 |
Why?
|
Long QT Syndrome | 1 | 2007 | 16 | 0.090 |
Why?
|
Genome, Human | 1 | 2007 | 57 | 0.090 |
Why?
|
Drosophila melanogaster | 2 | 2021 | 21 | 0.090 |
Why?
|
Serotonin Uptake Inhibitors | 2 | 2006 | 90 | 0.080 |
Why?
|
Blotting, Western | 3 | 2012 | 235 | 0.080 |
Why?
|
Long-Term Potentiation | 1 | 2006 | 12 | 0.080 |
Why?
|
Central Nervous System Agents | 1 | 2006 | 8 | 0.080 |
Why?
|
Drug Eruptions | 1 | 2006 | 18 | 0.080 |
Why?
|
Cerebellar Ataxia | 1 | 2006 | 7 | 0.080 |
Why?
|
Dermatoglyphics | 1 | 2006 | 2 | 0.080 |
Why?
|
Frameshift Mutation | 1 | 2006 | 6 | 0.080 |
Why?
|
Codon, Nonsense | 1 | 2006 | 4 | 0.080 |
Why?
|
Penetrance | 1 | 2006 | 3 | 0.080 |
Why?
|
3' Untranslated Regions | 1 | 2006 | 4 | 0.080 |
Why?
|
Tobacco Smoke Pollution | 1 | 2006 | 7 | 0.080 |
Why?
|
Synaptic Transmission | 1 | 2006 | 47 | 0.080 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factors | 1 | 2006 | 3 | 0.080 |
Why?
|
Research | 2 | 2017 | 62 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 594 | 0.080 |
Why?
|
Neuronal Plasticity | 1 | 2006 | 50 | 0.080 |
Why?
|
Brain Mapping | 2 | 2005 | 196 | 0.080 |
Why?
|
Facies | 1 | 2005 | 2 | 0.080 |
Why?
|
Diagnosis, Differential | 4 | 2009 | 469 | 0.080 |
Why?
|
Blood Pressure | 1 | 2007 | 250 | 0.080 |
Why?
|
Gait Ataxia | 1 | 2005 | 4 | 0.080 |
Why?
|
Neuroprotective Agents | 1 | 2006 | 66 | 0.080 |
Why?
|
Amyloid | 1 | 2005 | 50 | 0.080 |
Why?
|
Memory, Short-Term | 3 | 2010 | 98 | 0.080 |
Why?
|
Tumor Cells, Cultured | 3 | 1998 | 157 | 0.080 |
Why?
|
Nutritional Requirements | 1 | 2005 | 21 | 0.080 |
Why?
|
Visual Perception | 2 | 2008 | 70 | 0.080 |
Why?
|
Hippocampus | 3 | 2019 | 286 | 0.070 |
Why?
|
Contractile Proteins | 1 | 2005 | 6 | 0.070 |
Why?
|
Body Height | 1 | 2005 | 44 | 0.070 |
Why?
|
Diagnostic Errors | 1 | 2005 | 48 | 0.070 |
Why?
|
Ehlers-Danlos Syndrome | 1 | 2005 | 5 | 0.070 |
Why?
|
Sequence Deletion | 1 | 2005 | 20 | 0.070 |
Why?
|
Microfilament Proteins | 1 | 2005 | 32 | 0.070 |
Why?
|
Mass Screening | 1 | 2007 | 199 | 0.070 |
Why?
|
Receptors, Cholecystokinin | 1 | 2004 | 5 | 0.070 |
Why?
|
Body Weight | 1 | 2005 | 165 | 0.070 |
Why?
|
Mice, Inbred C57BL | 2 | 2019 | 538 | 0.070 |
Why?
|
Risk Assessment | 2 | 2021 | 804 | 0.070 |
Why?
|
Psychopharmacology | 1 | 2004 | 2 | 0.070 |
Why?
|
Karyotyping | 2 | 1994 | 15 | 0.070 |
Why?
|
Cerebral Infarction | 1 | 2005 | 158 | 0.070 |
Why?
|
Neurologic Examination | 3 | 2012 | 160 | 0.070 |
Why?
|
Factor Analysis, Statistical | 2 | 2014 | 75 | 0.070 |
Why?
|
Reference Values | 2 | 2020 | 258 | 0.070 |
Why?
|
Amniocentesis | 2 | 2000 | 2 | 0.070 |
Why?
|
California | 2 | 2018 | 34 | 0.060 |
Why?
|
Videotape Recording | 1 | 2003 | 49 | 0.060 |
Why?
|
DNA Primers | 3 | 2012 | 66 | 0.060 |
Why?
|
Platelet Count | 2 | 2001 | 25 | 0.060 |
Why?
|
Epilepsy, Rolandic | 1 | 2002 | 1 | 0.060 |
Why?
|
Activities of Daily Living | 2 | 2017 | 472 | 0.060 |
Why?
|
Central Nervous System | 1 | 2003 | 58 | 0.060 |
Why?
|
Electromyography | 2 | 2013 | 90 | 0.060 |
Why?
|
Risk | 3 | 2013 | 232 | 0.060 |
Why?
|
1-Methyl-3-isobutylxanthine | 3 | 1993 | 6 | 0.060 |
Why?
|
Colforsin | 3 | 1993 | 13 | 0.060 |
Why?
|
Molecular Sequence Data | 2 | 2010 | 316 | 0.060 |
Why?
|
Enkephalin, Leucine-2-Alanine | 3 | 1988 | 3 | 0.060 |
Why?
|
Lymphocytes | 2 | 2008 | 116 | 0.060 |
Why?
|
Dietary Carbohydrates | 1 | 2001 | 16 | 0.060 |
Why?
|
Dietary Fats | 1 | 2001 | 39 | 0.060 |
Why?
|
Hypoglycemia | 1 | 2001 | 18 | 0.060 |
Why?
|
Fertility | 1 | 2021 | 16 | 0.060 |
Why?
|
Animals, Genetically Modified | 1 | 2021 | 18 | 0.060 |
Why?
|
Pyrimidinones | 1 | 2021 | 4 | 0.060 |
Why?
|
Biological Assay | 1 | 2021 | 9 | 0.060 |
Why?
|
Morpholines | 1 | 2021 | 16 | 0.060 |
Why?
|
Neurogenesis | 1 | 2021 | 12 | 0.060 |
Why?
|
Pituitary-Adrenal System | 1 | 2021 | 17 | 0.060 |
Why?
|
Organoids | 1 | 2021 | 9 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 206 | 0.060 |
Why?
|
Proteome | 1 | 2021 | 23 | 0.060 |
Why?
|
Task Performance and Analysis | 2 | 2013 | 58 | 0.060 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2021 | 29 | 0.060 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2021 | 44 | 0.060 |
Why?
|
Cell Lineage | 1 | 2021 | 35 | 0.060 |
Why?
|
Brain Diseases, Metabolic, Inborn | 1 | 2020 | 2 | 0.060 |
Why?
|
Mental Retardation, X-Linked | 1 | 2020 | 2 | 0.060 |
Why?
|
Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2020 | 2 | 0.060 |
Why?
|
Vesicular Transport Proteins | 1 | 2020 | 9 | 0.060 |
Why?
|
Creatine | 1 | 2020 | 5 | 0.060 |
Why?
|
Reference Standards | 2 | 2013 | 36 | 0.060 |
Why?
|
Click Chemistry | 1 | 2020 | 1 | 0.050 |
Why?
|
Incidence | 3 | 2014 | 827 | 0.050 |
Why?
|
Cycloaddition Reaction | 1 | 2020 | 2 | 0.050 |
Why?
|
Clonidine | 3 | 1985 | 31 | 0.050 |
Why?
|
Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2021 | 171 | 0.050 |
Why?
|
Social Skills | 1 | 2020 | 14 | 0.050 |
Why?
|
Time and Motion Studies | 1 | 2020 | 13 | 0.050 |
Why?
|
Peptide Hydrolases | 1 | 2000 | 21 | 0.050 |
Why?
|
Foot | 1 | 2020 | 36 | 0.050 |
Why?
|
Piperazines | 1 | 2021 | 98 | 0.050 |
Why?
|
Risperidone | 1 | 2019 | 5 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2020 | 33 | 0.050 |
Why?
|
Genitalia | 1 | 1999 | 2 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2021 | 238 | 0.050 |
Why?
|
Cats | 1 | 2020 | 82 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 308 | 0.050 |
Why?
|
Databases, Genetic | 1 | 2019 | 12 | 0.050 |
Why?
|
Endopeptidases | 1 | 2000 | 58 | 0.050 |
Why?
|
Workflow | 1 | 2019 | 10 | 0.050 |
Why?
|
Codon, Terminator | 1 | 2019 | 2 | 0.050 |
Why?
|
Gene Rearrangement | 1 | 2019 | 16 | 0.050 |
Why?
|
Dental Care | 1 | 2019 | 3 | 0.050 |
Why?
|
Hexokinase | 1 | 2019 | 1 | 0.050 |
Why?
|
Immunization | 1 | 2019 | 49 | 0.050 |
Why?
|
Research Design | 1 | 2021 | 230 | 0.050 |
Why?
|
ras Proteins | 1 | 2019 | 14 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 47 | 0.050 |
Why?
|
Pregnancy | 2 | 2017 | 452 | 0.050 |
Why?
|
Trisomy | 1 | 1998 | 3 | 0.050 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 1998 | 8 | 0.050 |
Why?
|
Vaccination | 1 | 2019 | 42 | 0.050 |
Why?
|
ROC Curve | 1 | 2019 | 155 | 0.050 |
Why?
|
New York | 1 | 2018 | 14 | 0.050 |
Why?
|
Biological Specimen Banks | 1 | 2018 | 7 | 0.050 |
Why?
|
Skin | 2 | 2012 | 144 | 0.050 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 298 | 0.050 |
Why?
|
Michigan | 1 | 2018 | 20 | 0.050 |
Why?
|
Influenza, Human | 1 | 2019 | 63 | 0.050 |
Why?
|
Population Surveillance | 1 | 2019 | 129 | 0.050 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 1998 | 43 | 0.050 |
Why?
|
Organ Size | 1 | 2018 | 122 | 0.050 |
Why?
|
Models, Biological | 1 | 2021 | 428 | 0.050 |
Why?
|
Muscle Hypotonia | 1 | 2017 | 3 | 0.050 |
Why?
|
Self Report | 1 | 2019 | 217 | 0.050 |
Why?
|
Glycosylphosphatidylinositols | 1 | 2017 | 8 | 0.040 |
Why?
|
Phosphorylation | 2 | 2008 | 196 | 0.040 |
Why?
|
Hearing Loss, High-Frequency | 1 | 2017 | 1 | 0.040 |
Why?
|
Hydroxycholesterols | 1 | 2017 | 1 | 0.040 |
Why?
|
Calbindins | 1 | 2017 | 3 | 0.040 |
Why?
|
Dependovirus | 2 | 2008 | 36 | 0.040 |
Why?
|
Parental Consent | 1 | 2017 | 2 | 0.040 |
Why?
|
Neuroimaging | 1 | 2018 | 122 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2019 | 115 | 0.040 |
Why?
|
Injections, Spinal | 1 | 2017 | 54 | 0.040 |
Why?
|
Organizational Objectives | 1 | 2017 | 27 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2017 | 54 | 0.040 |
Why?
|
Treatment Failure | 1 | 2017 | 188 | 0.040 |
Why?
|
Kinetics | 3 | 1996 | 278 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2016 | 35 | 0.040 |
Why?
|
Mice, Transgenic | 2 | 2008 | 301 | 0.040 |
Why?
|
Odds Ratio | 2 | 2011 | 328 | 0.040 |
Why?
|
Prognosis | 2 | 2013 | 1045 | 0.040 |
Why?
|
Breath Holding | 1 | 2016 | 2 | 0.040 |
Why?
|
Receptors, Opioid, kappa | 1 | 1996 | 3 | 0.040 |
Why?
|
Radiography | 2 | 2012 | 714 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 83 | 0.040 |
Why?
|
Gene Amplification | 1 | 1995 | 29 | 0.040 |
Why?
|
Neuroglia | 1 | 1996 | 47 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 41 | 0.040 |
Why?
|
Motor Skills | 1 | 2016 | 64 | 0.040 |
Why?
|
Caregivers | 1 | 2017 | 147 | 0.040 |
Why?
|
Minisatellite Repeats | 2 | 2006 | 8 | 0.040 |
Why?
|
Retinoid X Receptor alpha | 1 | 2015 | 5 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2015 | 61 | 0.040 |
Why?
|
PPAR-beta | 1 | 2015 | 5 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 44 | 0.040 |
Why?
|
Tretinoin | 1 | 2015 | 21 | 0.040 |
Why?
|
Corpus Callosum | 1 | 2015 | 18 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2015 | 9 | 0.040 |
Why?
|
PPAR gamma | 1 | 2015 | 17 | 0.040 |
Why?
|
Lysosomes | 1 | 2015 | 24 | 0.040 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 101 | 0.040 |
Why?
|
Lipid Metabolism | 1 | 2015 | 51 | 0.040 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 1994 | 3 | 0.040 |
Why?
|
Restriction Mapping | 1 | 1994 | 5 | 0.040 |
Why?
|
Rats | 3 | 2006 | 954 | 0.040 |
Why?
|
Range of Motion, Articular | 1 | 2018 | 697 | 0.040 |
Why?
|
Protein Binding | 1 | 2015 | 156 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 1994 | 14 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2014 | 31 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 24 | 0.040 |
Why?
|
Exercise | 1 | 2019 | 431 | 0.040 |
Why?
|
In Vitro Techniques | 2 | 2011 | 247 | 0.040 |
Why?
|
beta-N-Acetylhexosaminidases | 1 | 1994 | 1 | 0.030 |
Why?
|
Sandhoff Disease | 1 | 1994 | 1 | 0.030 |
Why?
|
Georgia | 1 | 2014 | 16 | 0.030 |
Why?
|
Motor Neuron Disease | 1 | 1994 | 5 | 0.030 |
Why?
|
Palate | 1 | 1994 | 5 | 0.030 |
Why?
|
Optic Disk | 1 | 1994 | 4 | 0.030 |
Why?
|
Congenital Hypothyroidism | 1 | 1994 | 3 | 0.030 |
Why?
|
Maryland | 1 | 2013 | 10 | 0.030 |
Why?
|
Sex Distribution | 1 | 2014 | 91 | 0.030 |
Why?
|
Fatal Outcome | 1 | 1994 | 76 | 0.030 |
Why?
|
Myotonin-Protein Kinase | 1 | 2013 | 1 | 0.030 |
Why?
|
Aging | 1 | 2004 | 1551 | 0.030 |
Why?
|
Mitochondrial Membranes | 1 | 2013 | 4 | 0.030 |
Why?
|
Inheritance Patterns | 1 | 2013 | 7 | 0.030 |
Why?
|
Genomic Instability | 1 | 2013 | 8 | 0.030 |
Why?
|
MEF2 Transcription Factors | 1 | 2013 | 3 | 0.030 |
Why?
|
Radioimmunoassay | 1 | 1993 | 24 | 0.030 |
Why?
|
Fecal Incontinence | 1 | 2012 | 9 | 0.030 |
Why?
|
Cell Membrane | 2 | 1984 | 129 | 0.030 |
Why?
|
Urinary Incontinence | 1 | 2012 | 25 | 0.030 |
Why?
|
Hypothyroidism | 1 | 1994 | 73 | 0.030 |
Why?
|
Health Policy | 1 | 2013 | 49 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2014 | 162 | 0.030 |
Why?
|
Brefeldin A | 1 | 2012 | 3 | 0.030 |
Why?
|
Golgi Apparatus | 1 | 2012 | 6 | 0.030 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2012 | 10 | 0.030 |
Why?
|
Glycosylation | 1 | 2012 | 24 | 0.030 |
Why?
|
Movement | 1 | 2013 | 167 | 0.030 |
Why?
|
Dystonia | 1 | 2012 | 55 | 0.030 |
Why?
|
Protein Transport | 1 | 2012 | 42 | 0.030 |
Why?
|
Microsatellite Repeats | 2 | 2005 | 22 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2012 | 88 | 0.030 |
Why?
|
Social Adjustment | 1 | 2012 | 32 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2012 | 63 | 0.030 |
Why?
|
Second Messenger Systems | 1 | 1992 | 5 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 149 | 0.030 |
Why?
|
Gene Duplication | 1 | 2011 | 4 | 0.030 |
Why?
|
Gene Knock-In Techniques | 1 | 2011 | 10 | 0.030 |
Why?
|
Lewy Body Disease | 1 | 2012 | 103 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2011 | 29 | 0.030 |
Why?
|
Gene Expression | 2 | 2008 | 271 | 0.030 |
Why?
|
Arrhythmia, Sinus | 1 | 2011 | 2 | 0.030 |
Why?
|
Organ Specificity | 1 | 2011 | 57 | 0.030 |
Why?
|
Respiratory Rate | 1 | 2011 | 6 | 0.030 |
Why?
|
Gene Dosage | 1 | 2011 | 26 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2012 | 501 | 0.030 |
Why?
|
Hydrogen Peroxide | 1 | 2011 | 45 | 0.030 |
Why?
|
LIM Domain Proteins | 1 | 2011 | 3 | 0.030 |
Why?
|
Epilepsies, Myoclonic | 1 | 2011 | 4 | 0.030 |
Why?
|
Embryo, Nonmammalian | 1 | 2011 | 9 | 0.030 |
Why?
|
Monitoring, Ambulatory | 1 | 2011 | 23 | 0.030 |
Why?
|
Recurrence | 1 | 2012 | 390 | 0.030 |
Why?
|
Zebrafish | 1 | 2011 | 22 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 55 | 0.030 |
Why?
|
Limit of Detection | 1 | 2010 | 4 | 0.030 |
Why?
|
Down-Regulation | 1 | 2011 | 132 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 2011 | 61 | 0.030 |
Why?
|
Weight Gain | 1 | 2011 | 68 | 0.030 |
Why?
|
Electron Transport | 1 | 2010 | 5 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2010 | 46 | 0.030 |
Why?
|
Apoptosis | 1 | 2012 | 291 | 0.030 |
Why?
|
Depression | 1 | 2015 | 502 | 0.030 |
Why?
|
Tracheotomy | 1 | 2010 | 4 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 93 | 0.030 |
Why?
|
Nuclear Family | 1 | 2010 | 17 | 0.030 |
Why?
|
Intelligence Tests | 1 | 2010 | 18 | 0.030 |
Why?
|
Lamins | 1 | 2009 | 2 | 0.030 |
Why?
|
Transfection | 3 | 1996 | 153 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2010 | 77 | 0.030 |
Why?
|
Fathers | 1 | 2010 | 24 | 0.030 |
Why?
|
Mood Disorders | 1 | 2009 | 36 | 0.020 |
Why?
|
Rotarod Performance Test | 1 | 2008 | 9 | 0.020 |
Why?
|
Reversal Learning | 1 | 2008 | 1 | 0.020 |
Why?
|
Acoustic Stimulation | 1 | 2009 | 67 | 0.020 |
Why?
|
Polysomnography | 1 | 2009 | 102 | 0.020 |
Why?
|
Canada | 1 | 2008 | 56 | 0.020 |
Why?
|
Thymus Gland | 1 | 2008 | 28 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2008 | 69 | 0.020 |
Why?
|
Random Allocation | 1 | 2008 | 162 | 0.020 |
Why?
|
2-Chloroadenosine | 1 | 1988 | 1 | 0.020 |
Why?
|
Calcimycin | 1 | 1988 | 5 | 0.020 |
Why?
|
Protein Kinases | 1 | 1988 | 17 | 0.020 |
Why?
|
Adenosine | 1 | 1988 | 16 | 0.020 |
Why?
|
Electrocardiography, Ambulatory | 1 | 2008 | 23 | 0.020 |
Why?
|
Societies, Medical | 1 | 2010 | 203 | 0.020 |
Why?
|
Immunoassay | 1 | 1988 | 44 | 0.020 |
Why?
|
Tyrosine 3-Monooxygenase | 1 | 1988 | 84 | 0.020 |
Why?
|
Mutagenesis, Insertional | 1 | 2007 | 4 | 0.020 |
Why?
|
Receptor, trkB | 1 | 2007 | 4 | 0.020 |
Why?
|
Baroreflex | 1 | 2007 | 2 | 0.020 |
Why?
|
Heart Function Tests | 1 | 2007 | 5 | 0.020 |
Why?
|
Sleep Disorders, Intrinsic | 1 | 2007 | 7 | 0.020 |
Why?
|
Catecholamines | 1 | 2007 | 18 | 0.020 |
Why?
|
Medical History Taking | 1 | 2007 | 26 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2007 | 35 | 0.020 |
Why?
|
Focus Groups | 1 | 2007 | 91 | 0.020 |
Why?
|
Gene Silencing | 1 | 2007 | 26 | 0.020 |
Why?
|
Cholinesterase Inhibitors | 1 | 2006 | 20 | 0.020 |
Why?
|
Carbidopa | 1 | 2006 | 45 | 0.020 |
Why?
|
Fingers | 1 | 2006 | 13 | 0.020 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2006 | 2 | 0.020 |
Why?
|
Inclusion Bodies | 1 | 2006 | 15 | 0.020 |
Why?
|
Benzodiazepines | 1 | 2006 | 59 | 0.020 |
Why?
|
Calcium | 1 | 2011 | 501 | 0.020 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2006 | 45 | 0.020 |
Why?
|
Receptors, Neurotransmitter | 1 | 1986 | 6 | 0.020 |
Why?
|
Tunicamycin | 1 | 1986 | 3 | 0.020 |
Why?
|
Cell Death | 1 | 2006 | 67 | 0.020 |
Why?
|
Dopamine Agonists | 1 | 2006 | 46 | 0.020 |
Why?
|
Alkaloids | 1 | 1986 | 8 | 0.020 |
Why?
|
Chicago | 1 | 2010 | 945 | 0.020 |
Why?
|
Glucosamine | 1 | 1986 | 15 | 0.020 |
Why?
|
G(M2) Ganglioside | 1 | 1985 | 1 | 0.020 |
Why?
|
Cholera Toxin | 1 | 1985 | 2 | 0.020 |
Why?
|
G(M1) Ganglioside | 1 | 1985 | 2 | 0.020 |
Why?
|
Levodopa | 1 | 2006 | 138 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2008 | 169 | 0.020 |
Why?
|
Chromatography, Thin Layer | 1 | 1985 | 5 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 1986 | 45 | 0.020 |
Why?
|
Glycoproteins | 1 | 1986 | 66 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 631 | 0.020 |
Why?
|
Behavior, Animal | 1 | 2006 | 109 | 0.020 |
Why?
|
Filamins | 1 | 2005 | 3 | 0.020 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2005 | 6 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2005 | 41 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2005 | 105 | 0.020 |
Why?
|
CHO Cells | 2 | 1996 | 23 | 0.020 |
Why?
|
Spiperone | 1 | 1984 | 3 | 0.020 |
Why?
|
Prostaglandins E | 1 | 1984 | 5 | 0.020 |
Why?
|
Apomorphine | 1 | 1984 | 37 | 0.020 |
Why?
|
Vascular Diseases | 1 | 2005 | 58 | 0.020 |
Why?
|
Dopamine Agents | 1 | 2004 | 41 | 0.020 |
Why?
|
Clergy | 1 | 2005 | 83 | 0.020 |
Why?
|
Autopsy | 1 | 2005 | 334 | 0.020 |
Why?
|
Embryonic and Fetal Development | 1 | 2003 | 10 | 0.020 |
Why?
|
Genes, Dominant | 1 | 2003 | 15 | 0.020 |
Why?
|
Cerebral Amyloid Angiopathy | 1 | 2005 | 94 | 0.020 |
Why?
|
Dementia | 1 | 2009 | 509 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2005 | 385 | 0.020 |
Why?
|
Guanylyl Imidodiphosphate | 1 | 1983 | 1 | 0.020 |
Why?
|
Ribonucleotides | 1 | 1983 | 1 | 0.020 |
Why?
|
Clone Cells | 1 | 1983 | 22 | 0.020 |
Why?
|
Binding, Competitive | 1 | 1983 | 30 | 0.020 |
Why?
|
Enkephalins | 1 | 1983 | 2 | 0.020 |
Why?
|
Prostaglandins | 1 | 1983 | 4 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2003 | 23 | 0.020 |
Why?
|
Cations | 1 | 1983 | 16 | 0.020 |
Why?
|
European Continental Ancestry Group | 1 | 2003 | 66 | 0.020 |
Why?
|
Apolipoprotein E2 | 1 | 2002 | 6 | 0.020 |
Why?
|
Cerebellar Cortex | 1 | 2002 | 9 | 0.020 |
Why?
|
Apolipoprotein E3 | 1 | 2002 | 13 | 0.020 |
Why?
|
Ascorbic Acid | 1 | 1983 | 39 | 0.020 |
Why?
|
Cerebellar Diseases | 1 | 2002 | 11 | 0.020 |
Why?
|
Cerebral Ventricles | 1 | 2002 | 27 | 0.020 |
Why?
|
Chronic Disease | 1 | 2005 | 542 | 0.020 |
Why?
|
Narcotics | 1 | 1983 | 33 | 0.020 |
Why?
|
Mental Recall | 1 | 2002 | 74 | 0.020 |
Why?
|
Linear Models | 1 | 2003 | 277 | 0.010 |
Why?
|
Urban Population | 1 | 2003 | 158 | 0.010 |
Why?
|
Stroke | 1 | 2005 | 345 | 0.010 |
Why?
|
Patient Selection | 1 | 2003 | 259 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 162 | 0.010 |
Why?
|
alpha-Fetoproteins | 1 | 1998 | 7 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 1998 | 20 | 0.010 |
Why?
|
Phospholipase D | 1 | 1996 | 5 | 0.010 |
Why?
|
Type C Phospholipases | 1 | 1996 | 11 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1996 | 27 | 0.010 |
Why?
|
Neurofilament Proteins | 1 | 1996 | 6 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1996 | 35 | 0.010 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 1996 | 37 | 0.010 |
Why?
|
Antibodies | 1 | 1996 | 73 | 0.010 |
Why?
|
Methylation | 1 | 1994 | 8 | 0.010 |
Why?
|
Hexosaminidase A | 1 | 1994 | 1 | 0.010 |
Why?
|
Hexosaminidase B | 1 | 1994 | 1 | 0.010 |
Why?
|
Serine | 1 | 1994 | 15 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1994 | 24 | 0.010 |
Why?
|
Protein Structure, Secondary | 1 | 1994 | 28 | 0.010 |
Why?
|
Tyrosine | 1 | 1994 | 26 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1994 | 252 | 0.010 |
Why?
|
8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1993 | 3 | 0.010 |
Why?
|
Lysergic Acid | 1 | 1993 | 1 | 0.010 |
Why?
|
Biological Transport | 1 | 1993 | 47 | 0.010 |
Why?
|
Paroxetine | 1 | 1993 | 14 | 0.010 |
Why?
|
Glucose | 1 | 1993 | 69 | 0.010 |
Why?
|
Glioma | 1 | 1993 | 58 | 0.010 |
Why?
|
Prospective Studies | 1 | 1997 | 1891 | 0.010 |
Why?
|
Receptors, Opioid | 1 | 1986 | 1 | 0.010 |
Why?
|
Swainsonine | 1 | 1986 | 1 | 0.010 |
Why?
|
Receptors, Opioid, delta | 1 | 1986 | 1 | 0.010 |
Why?
|
Receptors, sigma | 1 | 1986 | 1 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1986 | 175 | 0.000 |
Why?
|